Group 1 - The core viewpoint of the article is that Xinzhi Group is expanding its global strategy by establishing a wholly-owned subsidiary in Singapore and a joint venture in Thailand to enhance its overseas business development [1] Group 2 - Xinzhi Group's wholly-owned subsidiary, Chongqing Xinzhi, will invest in the establishment of Xinzhi Overseas Management Co., Ltd. in Singapore using self-raised funds [1] - The Singapore subsidiary will partner with Zhejiang Xinge to invest 99.99% and 0.01% respectively in the establishment of Xinzhi Electric (Thailand) Co., Ltd. in Thailand [1] - The total investment for this overseas project is $40 million, sourced entirely from the company's domestic self-raised funds, aimed at setting up and operating overseas companies, purchasing land, constructing factories, acquiring equipment, and covering working capital [1]

信质集团公告，公司全资子公司信质电机（重庆）有限公司拟通过在新加坡设立全资孙公司信质海外管 理有限公司作为路径公司，并与公司全资子公司浙江信戈制冷设备科技有限公司在泰国设立信质电机 （泰国）有限公司。总投资额为4000万美元，资金来源为公司自有（自筹）资金。该投资旨在完善公司 全球化战略布局，推动海外业务发展，快速响应客户需求。 来源：滚动播报 ...

Core Viewpoint - Xianle Health, a leading health supplement OEM, has submitted an application for a dual listing on the Hong Kong Stock Exchange, while simultaneously announcing a significant decline in net profit for the previous year [1][2] Group 1: Company Performance - Xianle Health's revenue for 2023, 2024, and the first three quarters of 2025 is projected to be 3.582 billion, 4.211 billion, and 3.291 billion yuan respectively, with net profit growth rates declining significantly to 32.39%, 15.66%, and 8.53% [1] - The company expects a net profit attributable to shareholders for 2025 to be between 101 million and 151 million yuan, representing a year-on-year decline of 53% to 69% [2] - The net profit margin for the same periods is reported at 6.71%, 6.7%, and 6.74%, indicating a stable but low profitability [1] Group 2: Business Strategy and Adjustments - The decline in net profit is attributed to a one-time asset impairment loss of 195 million yuan from the personal care business, which has been underperforming and is being divested [2] - The company is focusing on strategic consulting projects and investments in emerging sectors such as precision nutrition and pet nutrition, which have incurred initial costs affecting profit margins [2] - A new stock incentive plan has been proposed, aiming to grant 2.2025 million restricted shares to 85 key personnel, with revenue targets set for 2026 to 2028 but no profit-related metrics, raising concerns among investors [3] Group 3: Market Outlook and Analyst Opinions - Analysts express optimism regarding Xianle Health's growth in European and Asia-Pacific markets, suggesting that the company can leverage international capital markets to enhance its global strategy [4] - The divestment of the personal care business allows the company to concentrate on its core operations, potentially leading to improved profitability and growth in both domestic and international markets [4] - Analysts recommend monitoring the company's performance as it aims for accelerated growth in emerging channels and overseas markets [4]

证券代码：688202 证券简称：美迪西 公告编号：2026-003 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示: ● 经上海美迪西生物医药股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年度将出现亏 损，公司实现归属于母公司所有者的净利润为-18,600万元到-12,400万元，与上年同期（法定披露数 据）相比，亏损预计减少14,485万元到20,685万元，同比减亏43.78%至62.52%。 ● 预计2025年年度实现归属于母公司所有者的扣除非经常性损益后的净利润为-20,400万元到-13,600万 元，与上年同期（法定披露数据）相比，亏损预计减少14,371万元到21,171万元，同比减亏41.33%至 60.89%。 一、本期业绩预告情况 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 （1）经公司财务部门初步测算，预计2025年年度实现归属于母公司所有者的净利润为-18,600万元 到-12,400万元，与上年同期（法定披露数据）相比，亏损 ...

格隆汇1月30日丨美迪西(688202.SH)公布，经公司财务部门初步测算，预计2025年度将出现亏损，公司 实现归属于母公司所有者的净利润为-18,600万元到-12,400万元，与上年同期（法定披露数据）相比， 亏损预计减少14,485万元到20,685万元，同比减亏43.78%至62.52%。预计2025年年度实现归属于母公司 所有者的扣除非经常性损益后的净利润为-20,400万元到-13,600万元，与上年同期（法定披露数据）相 比，亏损预计减少14,371万元到21,171万元，同比减亏41.33%至60.89%。 报告期内，公司归属于母公司所有者的净利润以及归属于母公司所有者的扣除非经常性损益后的净利润 较上年同期实现大幅减亏，主要系公司加快全球化战略布局，充分发挥研发平台资源和优势，实现营业 收入预计同比增长约12%，其中境外主营业务收入占比预计提升至约47%。公司在推动营业收入增长的 同时，持续深化降本增效，加强成本管控，综合毛利率预计同比提升约11个百分点，盈利能力稳步改 善，实现亏损规模大幅收窄。 ...

格隆汇1月30日丨美迪西(688202.SH)公布，经公司财务部门初步测算，预计2025年度将出现亏损，公司 实现归属于母公司所有者的净利润为-18,600万元到-12,400万元，与上年同期（法定披露数据）相比， 亏损预计减少14,485万元到20,685万元，同比减亏43.78%至62.52%。预计2025年年度实现归属于母公司 所有者的扣除非经常性损益后的净利润为-20,400万元到-13,600万元，与上年同期（法定披露数据）相 比，亏损预计减少14,371万元到21,171万元，同比减亏41.33%至60.89%。 报告期内，公司归属于母公司所有者的净利润以及归属于母公司所有者的扣除非经常性损益后的净利润 较上年同期实现大幅减亏，主要系公司加快全球化战略布局，充分发挥研发平台资源和优势，实现营业 收入预计同比增长约12%，其中境外主营业务收入占比预计提升至约47%。公司在推动营业收入增长的 同时，持续深化降本增效，加强成本管控，综合毛利率预计同比提升约11个百分点，盈利能力稳步改 善，实现亏损规模大幅收窄。 ...

（记者 王晓波） 每经头条（nbdtoutiao）——核电建设热潮下，设备厂忙到"飞起"！订单已排至2028年，员工三班倒， 产线24小时不停 每经AI快讯，美迪西1月30日晚间发布业绩预告，预计2025年年度实现归属于母公司所有者的净利润 为-1.86亿元到-1.24亿元，与上年同期相比，亏损预计减少约1.45亿元~2.07亿元，同比减亏 43.78%~62.52%。业绩变动主要原因是，报告期内，公司归属于母公司所有者的净利润以及归属于母公 司所有者的扣除非经常性损益后的净利润较上年同期实现大幅减亏，主要系公司加快全球化战略布局， 充分发挥研发平台资源和优势，实现营业收入预计同比增长约12%，其中境外主营业务收入占比预计提 升至约47%。公司在推动营业收入增长的同时，持续深化降本增效，加强成本管控，综合毛利率预计同 比提升约11个百分点，盈利能力稳步改善，实现亏损规模大幅收窄。 ...

美迪西1月30日公告，预计2025年度归母净利润亏损1.24亿元-1.86亿元，上年同期亏损3.31亿元。该公 司称，报告期内，公司归属于母公司所有者的净利润较上年同期实现大幅减亏，主要系公司加快全球化 战略布局，充分发挥研发平台资源和优势，实现营业收入预计同比增长约12%，其中境外主营业务收入 占比预计提升至约 47%。公司在推动营业收入增长的同时，持续深化降本增效，加强成本管控，综合 毛利率预计同比提升约11个百分点，盈利能力稳步改善，实现亏损规模大幅收窄。 ...

Group 1 - The company expects a positive net profit for the year 2025, but it will show a downward trend compared to the previous year [1] - The performance forecast period is from January 1, 2025, to December 31, 2025 [1] Group 2 - External environmental pressures, including a complex international trade environment and short-term product structure adjustments by clients, are impacting the company's revenue and gross profit [2] - Strategic investments, such as the establishment of a production base in Thailand, are leading to significant initial costs due to supply chain setup and local team development, which are affecting short-term profitability [2] - Currency fluctuations, particularly the appreciation of the RMB against the USD, are putting pressure on gross margins and foreign exchange gains/losses [2]

Group 1 - The company expects a net profit loss attributable to shareholders of 44 million to 57 million yuan for 2025, compared to a loss of approximately 150 million yuan in the same period last year [1] - The company is focusing on strengthening internal management, promoting cost reduction and efficiency improvement, and upgrading processes, while maintaining stable overall production and operation despite market fluctuations [1] - The company is adjusting part of its production capacity based on industry competition and development trends, and is continuing to advance its globalization strategy [1] Group 2 - The company is enhancing sales price control to improve product profitability, leading to an improvement in overall gross margin compared to the same period last year [1] - The company is intensifying efforts to collect accounts receivable, resulting in a decrease in credit impairment losses compared to the previous year [1] - The company has deepened expense control, leading to a reduction in period expenses compared to the same period last year [1]